{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:49:14Z","timestamp":1782107354621,"version":"3.54.5"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Lecanemab is a monoclonal antibody targeting amyloid-beta (A\u03b2) approved for treating Alzheimer\u2019s disease (AD) with mild cognitive impairment or mild dementia. Continuous monitoring of its real-world safety profile remains essential. This study aimed to analyze lecanemab-related adverse events (AEs) using the FDA Adverse Event Reporting System (FAERS) database and a multicenter cohort, and explored mechanisms via network pharmacology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an updated disproportionality analysis of FAERS data from 2023 to 2024 to identify disproportionate reporting signals (SDRs). A multicenter retrospective cohort study was performed, including lecanemab users from June 2024 to February 2025. Data were collected from electronic medical records of five tertiary hospitals. AEs were identified and influencing factors of AE occurrence were analyzed. Additionally, a drug-gene interaction network was constructed to explore potential mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the FAERS analysis of 2,764 AEs from 1,389 lecanemab users, 12 of 41 positive SDRs were prioritized, with 75% (9\/12) being nervous system disorders, primarily amyloid-related imaging abnormalities (ARIA). In the cohort study, 29.05% (43\/148) of patients experienced AEs, with infusion-related reactions being most common. Age was identified as a risk factor for AE occurrence [OR (95% CI): 1.109 (1.011\u20131.215), P\u00a0=\u00a00.028], while pre-treatment significantly reduced AE incidence. Gene enrichment analysis suggested potential links between lecanemab-related genes and AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study provides real-world evidence on the risk profile of lecanemab, highlighting the importance of continued safety monitoring. These findings may inform discussions about the risks associated with anti-amyloid treatments and warrant further confirmation in large-scale prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1822543","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:38:37Z","timestamp":1782106717000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaoxuan","family":"Xing","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing United Family Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhuhai People\u2019s Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University)","place":["Zhuhai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhe","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer's disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Dement"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(22)00009-3","article-title":"Will dementia hamper healthy ageing","volume":"7","author":"The Lancet Public H","year":"2022","journal-title":"Lancet Public Health"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-024-01144-2","article-title":"Incidence and prevalence of Alzheimer's disease in China: a systematic review and meta-analysis","volume":"39","author":"Ji","year":"2024","journal-title":"Eur J Epidemiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2022-100751","article-title":"The China alzheimer report 2022","volume":"35","author":"Ren","year":"2022","journal-title":"Gen Psychiatr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X18666200528142429","article-title":"Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease","volume":"18","author":"Khan","year":"2020","journal-title":"Curr Neuropharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119129","article-title":"A review on advances of treatment modalities for Alzheimer's disease","volume":"276","author":"Se Thoe","year":"2021","journal-title":"Life Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102203","article-title":"Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: a systematic review and network meta-analysis","volume":"94","author":"Terao","year":"2024","journal-title":"Ageing Res Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer's disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01851-2","article-title":"Lecanemab: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimer's Res Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p1580","article-title":"Alzheimer's disease: Lecanemab gets full FDA approval and black box safety warning","volume":"382","author":"Mahase","year":"2023","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","article-title":"Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"17","author":"Xing","year":"2025","journal-title":"Alzheimer's Res Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1559447","article-title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab","volume":"16","author":"Yan","year":"2025","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jad.2025.01.022","article-title":"Characteristics of adverse events and clinical risks of Lecanemab based on FAERS data","volume":"374","author":"Li","year":"2025","journal-title":"J Affect Disord"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251333084","article-title":"Adverse events associated with lecanemab: a disproportionality analysis of data from the FDA adverse event reporting system","volume":"105","author":"Li","year":"2025","journal-title":"J Alzheimers Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1561020","article-title":"A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases","volume":"16","author":"Hu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1593989","article-title":"Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system","volume":"16","author":"Kong","year":"2025","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251406619","article-title":"Real-world experience with baseline characteristics and safety of lecanemab for Alzheimer's disease in Eastern China","volume":"109","author":"Leng","year":"2026","journal-title":"J Alzheimers Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2018.02.014","article-title":"Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems","volume":"28","author":"Raschi","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/nu10101512","article-title":"On the reporting of odds ratios and risk ratios","volume":"10","author":"Pace","year":"2018","journal-title":"Nutrients"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000510703","article-title":"Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System","volume":"90","author":"Gastaldon","year":"2021","journal-title":"Psychother Psychosom"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/2047487320915663","article-title":"Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system","volume":"28","author":"Gatti","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b15-00243","article-title":"Association between selective serotonin reuptake inhibitor therapy and suicidality: analysis of U.S. Food and Drug Administration Adverse Event Reporting System data","volume":"38","author":"Umetsu","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"B28","unstructured":"Notice of the national medical products administration on the release of the guiding principles for the collection and reporting of adverse drug reactions (No. 131 of 2018)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14223","article-title":"Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab","volume":"20","author":"Gibson","year":"2024","journal-title":"Alzheimers Dement"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70021","article-title":"Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: the pharmacovigilance perspective","volume":"91","author":"Bobbins","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.12779\/dnd.2024.23.4.165","article-title":"Lecanemab: Appropriate use recommendations by Korean Dementia Association","volume":"23","author":"Park","year":"2024","journal-title":"Dement Neurocogn Disord"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100068","article-title":"Use of lecanemab and donanemab in the Canadian healthcare system: evidence, challenges, and areas for future research","volume":"12","author":"Smith","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100094","article-title":"Lecanemab for early Alzheimer's disease: appropriate use recommendations from the French federation of memory clinics","volume":"12","author":"Villain","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with anti-amyloid beta therapy","volume":"9","author":"Barakos","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab387","article-title":"VEGF signalling causes stalls in brain capillaries and reduces cerebral blood flow in Alzheimer's mice","volume":"145","author":"Ali","year":"2022","journal-title":"Brain"},{"key":"B43","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12974-024-03321-2","article-title":"Tension at the gate: sensing mechanical forces at the blood-brain barrier in health and disease","volume":"21","author":"Hansen","year":"2024","journal-title":"J Neuroinflamm"},{"key":"B44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13024-022-00542-y","article-title":"TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target","volume":"17","author":"Li","year":"2022","journal-title":"Mol Neurodegener"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.107064","article-title":"Synthesis and biological evaluations of 8-biaryl-2,2-dimethylbenzopyranamide derivatives against Alzheimer's disease and ischemic stroke","volume":"143","author":"Cao","year":"2024","journal-title":"Bioorg Chem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2015.00065","article-title":"Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's disease","volume":"9","author":"Canobbio","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2018.09.014","article-title":"Synthetic \u03b15\u03b21 integrin ligand PHSRN is proangiogenic and neuroprotective in cerebral ischemic stroke","volume":"185","author":"Wu","year":"2018","journal-title":"Biomaterials"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316526","article-title":"High-density lipoprotein carries markers that track with recovery from stroke","volume":"127","author":"Plubell","year":"2020","journal-title":"Circ Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-023-03447-x","article-title":"Identification of common core ion channel genes in epilepsy and Alzheimer's disease","volume":"193","author":"Tang","year":"2024","journal-title":"Ir J Med Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.18","article-title":"Plasticity of presynaptic and postsynaptic serotonin 1A receptors in an animal model of epilepsy-associated depression","volume":"36","author":"Pineda","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.biopha.2018.10.068","article-title":"Targeting gap junction in epilepsy: Perspectives and challenges","volume":"109","author":"Li","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B52","doi-asserted-by":"publisher","first-page":"6525","DOI":"10.1038\/s41467-024-50190-7","article-title":"Disease-relevant upregulation of P2Y1 receptor in astrocytes enhances neuronal excitability via IGFBP2","volume":"15","author":"Shigetomi","year":"2024","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-022-02966-5","article-title":"A review of molecular interplay between neurotrophins and miRNAs in neuropsychological disorders","volume":"59","author":"Abdolahi","year":"2022","journal-title":"Mol Neurobiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.100916","article-title":"Inflammation and cerebral small vessel disease: A systematic review","volume":"53","author":"Low","year":"2019","journal-title":"Ageing Res Rev"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109574","article-title":"IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer's disease","volume":"36","author":"Brigas","year":"2021","journal-title":"Cell Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-021-00889-6","article-title":"Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer's disease","volume":"29","author":"Dhapola","year":"2021","journal-title":"Inflammopharmacology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12974-023-02753-6","article-title":"Exercise suppresses neuroinflammation for alleviating Alzheimer's disease","volume":"20","author":"Wang","year":"2023","journal-title":"J Neuroinflamm"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1822543\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:38:42Z","timestamp":1782106722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1822543\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":57,"alternative-id":["10.3389\/fpsyt.2026.1822543"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1822543","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1822543"}}